Eve Radunz
A5072965548- SARS-CoV-2 and COVID-19 Research
- Animal Virus Infections Studies
- Viral gastroenteritis research and epidemiology
- Phytochemistry and Biological Activities
- Immunotherapy and Immune Responses
- Influenza Virus Research Studies
- Plant and Fungal Species Descriptions
- Plant Diversity and Evolution
The University of Sydney
2021
The University of Queensland
2020-2021
Efforts to develop and deploy effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue at pace. Here, we describe rational antigen design through manufacturability vaccine efficacy of a prefusion-stabilised spike (S) protein, Sclamp, in combination with the licensed adjuvant MF59 'MF59C.1' (Seqirus, Parkville, Australia).A panel recombinant Sclamp proteins were produced Chinese hamster ovary screened vitro select lead candidate. The structure this was...
Abstract Efforts to develop and deploy effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continue at pace with more than 30 candidate now in clinical evaluation. Here we describe the preclinical development of an adjuvanted, prefusion-stabilised Spike (S) protein “Sclamp” subunit vaccine, from rational antigen design through assessing manufacturability vaccine efficacy. In mice, elicits high levels neutralising antibodies epitopes both within outside...
A molecular phylogeny of Chloantheae (Lamiaceae) based on a three-marker chloroplast and nuclear DNA dataset was used to test the monophyly Lachnostachys Hook., Newcastelia F.Muell. Physopsis Turcz. clade consisting at least one species from each these genera recovered separately ‘core’ Lachnostachys, clades. The members this composite are here transferred new genus, Apatelantha T.C.Wilson & M.J.Henwood, which can be recognised by combination base style being glabrous or with only...
Efforts to develop and deploy effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continue at pace. Here we describe rational antigen design through manufacturability vaccine efficacy, of a prefusion-stabilised Spike (S) protein, Sclamp. This strategy uses an orthogonal stabilisation approach compared canonical vaccines, in combination with the licensed adjuvant MF59 (Seqirus). In mice, Sclamp elicits high levels neutralising antibodies, as well broadly...